Dosing Regimen for Cefotaxime Should Be Adapted to the Stage of Renal Dysfunction in Critically Ill Adult Patients-A Retrospective Study

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2024 Apr 26

PMID 38666989

Authors

Theo Dillies

Sophie Perinel-Ragey

Patricia Correia

Jerome Morel

Guillaume Thiery

Manon Launay

Affiliations

Soon will be listed here.

Abstract

Cefotaxime administration is recommended in doses of 3-12 g/day in adults with a Glomerular Filtration Rate (GFR) > 5 mL/min. This study aimed to assess the impact of renal function and obesity on cefotaxime concentrations in intensive care unit (ICU) patients. A retrospective cohort study was conducted on consecutive ICU patients receiving continuous cefotaxime infusion between 2020 and 2022 [IRBN992021/CHUSTE]. Doses were not constant; consequently, a concentration-to-dose ratio (C/D) was considered. Statistical analysis was performed to assess the relationship between cefotaxime concentrations, renal function, and obesity. A total of 70 patients, median age 61 years, were included, with no significant difference in cefotaxime concentrations between obese and non-obese patients. However, concentrations varied significantly by GFR, with underdosing prevalent in patients with normal to increased renal function and overdosing in those with severely impaired renal function. Adjustment of cefotaxime dosing according to GFR was associated with improved target attainment. Cefotaxime dosing in critically ill patients should consider renal function, with higher initial doses required in patients with normal to increased GFR and lower doses in those with severely impaired renal function. Therapeutic drug monitoring may aid in optimising dosing regimens. Prospective studies are warranted to validate these findings and inform clinical practice.

References

Hefny F, Stuart A, Kung J, Mahmoud S . Prevalence and Risk Factors of Augmented Renal Clearance: A Systematic Review and Meta-Analysis. Pharmaceutics. 2022; 14(2). PMC: 8878755. DOI: 10.3390/pharmaceutics14020445. View

Correia P, Launay M, Balluet R, Gergele L, Gauthier V, Morel J . Towards optimization of ceftazidime dosing in obese ICU patients: the end of the 'one-size-fits-all' approach?. J Antimicrob Chemother. 2023; 78(12):2968-2975. DOI: 10.1093/jac/dkad339. View

Ollivier J, Carrie C, dHoudain N, Djabarouti S, Petit L, Xuereb F . Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?. Antimicrob Agents Chemother. 2019; 63(3). PMC: 6395919. DOI: 10.1128/AAC.02134-18. View

Ferrer R, Martin-Loeches I, Phillips G, Osborn T, Townsend S, Dellinger R . Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014; 42(8):1749-55. DOI: 10.1097/CCM.0000000000000330. View

Dreesen E, Gijsen M, Elkayal O, Annaert P, Debaveye Y, Wauters J . Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia. J Antimicrob Chemother. 2022; 77(9):2479-2488. DOI: 10.1093/jac/dkac209. View

Roelofsen E, Abdulla A, Muller A, Endeman H, Gommers D, Dijkstra A . Dose optimization of cefotaxime as pre-emptive treatment in critically ill adult patients: A population pharmacokinetic study. Br J Clin Pharmacol. 2022; 89(2):705-713. PMC: 10087439. DOI: 10.1111/bcp.15487. View

Wong G, Briscoe S, McWhinney B, Ally M, Ungerer J, Lipman J . Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother. 2018; 73(11):3087-3094. DOI: 10.1093/jac/dky314. View

Fanton dAndon C, Correia P, Rigaill J, Kably B, Perinel-Ragey S, Launay M . Ceftazidime dosing in obese patients: is it time for more?. Expert Opin Drug Metab Toxicol. 2022; 18(4):277-284. DOI: 10.1080/17425255.2022.2080052. View

Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P . Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of.... Crit Care. 2019; 23(1):104. PMC: 6441232. DOI: 10.1186/s13054-019-2378-9. View

10.

Sakr Y, Alhussami I, Nanchal R, Wunderink R, Pellis T, Wittebole X . Being Overweight Is Associated With Greater Survival in ICU Patients: Results From the Intensive Care Over Nations Audit. Crit Care Med. 2015; 43(12):2623-32. DOI: 10.1097/CCM.0000000000001310. View

11.

Melo F, Macedo E, Fonseca Bezerra A, de Melo W, Mehta R, Burdmann E . A systematic review and meta-analysis of acute kidney injury in the intensive care units of developed and developing countries. PLoS One. 2020; 15(1):e0226325. PMC: 6968869. DOI: 10.1371/journal.pone.0226325. View

12.

Habib G, Lancellotti P, Antunes M, Bongiorni M, Casalta J, Del Zotti F . 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the.... Eur Heart J. 2015; 36(44):3075-3128. DOI: 10.1093/eurheartj/ehv319. View

13.

Swartling M, Smekal A, Furebring M, Lipcsey M, Jonsson S, Nielsen E . Population pharmacokinetics of cefotaxime in intensive care patients. Eur J Clin Pharmacol. 2021; 78(2):251-258. PMC: 8748331. DOI: 10.1007/s00228-021-03218-6. View

14.

Torres A, Niederman M, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H . International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the.... Eur Respir J. 2017; 50(3). DOI: 10.1183/13993003.00582-2017. View

15.

Sistanizad M, Hassanpour R, Pourheidar E . Are Antibiotics Appropriately Dosed in Critically Ill Patients with Augmented Renal Clearance? A Narrative Review. Int J Clin Pract. 2022; 2022:1867674. PMC: 9159163. DOI: 10.1155/2022/1867674. View

16.

Cheng V, Abdul-Aziz M, Burrows F, Buscher H, Cho Y, Corley A . Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study). Clin Pharmacokinet. 2022; 61(6):847-856. PMC: 9249724. DOI: 10.1007/s40262-021-01106-x. View

17.

Hartman S, Upadhyay P, Mathot R, van der Flier M, Schreuder M, Bruggemann R . Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children. J Antimicrob Chemother. 2022; 77(6):1725-1732. PMC: 9155601. DOI: 10.1093/jac/dkac095. View

18.

Guerra Valero Y, Dorofaeff T, Coulthard M, Sparkes L, Lipman J, Wallis S . Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?. J Antimicrob Chemother. 2022; 77(8):2227-2237. PMC: 9333413. DOI: 10.1093/jac/dkac168. View

19.

De Jong A, Verzilli D, Sebbane M, Monnin M, Belafia F, Cisse M . Medical Versus Surgical ICU Obese Patient Outcome: A Propensity-Matched Analysis to Resolve Clinical Trial Controversies. Crit Care Med. 2018; 46(4):e294-e301. DOI: 10.1097/CCM.0000000000002954. View